2024
Comparative Effectiveness of SBRT
Shen J, Sritharan D, Yu J, Aneja S. Comparative Effectiveness of SBRT. 2024, 455-467. DOI: 10.1007/978-3-031-67743-4_33.Peer-Reviewed Original ResearchStereotactic body radiation therapyEffect of stereotactic body radiation therapyAlternative to other treatment modalitiesStereotactic body radiation therapy treatmentLong-term follow-up of patientsFollow-up of patientsLong-term follow-upTreatment of brainOligometastatic diseaseRadiation therapyTreatment of cancerRetrospective seriesTreatment modalitiesRenal cancerCost-effectiveness studiesDatabase analysisCancerTreatmentProstateTherapyBeyond T cell exhaustion: TIM-3 regulation of myeloid cells
Dixon K, Lahore G, Kuchroo V. Beyond T cell exhaustion: TIM-3 regulation of myeloid cells. Science Immunology 2024, 9: eadf2223. PMID: 38457514, DOI: 10.1126/sciimmunol.adf2223.Peer-Reviewed Original ResearchConceptsT cell exhaustionTim-3CD8<sup>+</sup> T cellsImmune responseRegulation of myeloid cell functionT cell stemnessTim-3 regulationImmune checkpoint moleculesT cell immunoglobulinCell-extrinsic mechanismsMyeloid cell functionRegulation of myeloid cellsCheckpoint moleculesTreatment of cancerCD4<sup>+</sup>T cellsMyeloid cellsCell-intrinsicCell functionAutoimmunityAutoinflammationCancerImmunoglobulin
2023
Alterations in Cancer Treatment During the First Year of the COVID-19 Pandemic in the US
Janczewski L, Cotler J, Merkow R, Palis B, Nelson H, Mullett T, Boffa D. Alterations in Cancer Treatment During the First Year of the COVID-19 Pandemic in the US. JAMA Network Open 2023, 6: e2340148. PMID: 37902756, PMCID: PMC10616721, DOI: 10.1001/jamanetworkopen.2023.40148.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseCancer treatmentAcademic hospitalCommunity hospitalMAIN OUTCOMECOVID-19 pandemicProportion of patientsRetrospective cohort studyAvailability of treatmentFirst yearUnderwent surgeryCohort studyMedian ageCancer surgeryMedian timeTreatment of cancerCancer careTreatment modalitiesCancer screeningCancer DatabaseMedian travel distancePatientsHospitalSurgeryCancerLysine Demethylation in Pathogenesis
Cao J, Yan Q. Lysine Demethylation in Pathogenesis. Advances In Experimental Medicine And Biology 2023, 1433: 1-14. PMID: 37751133, DOI: 10.1007/978-3-031-38176-8_1.ChaptersConceptsLysine demethylasesLSD1/KDM1AHistone lysine methylationHistone lysine methyltransferasesMajor epigenetic mechanismsNormal developmentNon-histone substratesSpecific small molecule inhibitorsSmall molecule inhibitorsLysine methylationLysine methyltransferasesHistone methylationHistone lysineLysine demethylationEpigenetic mechanismsDNA repairArginine residuesHuman diseasesMore subfamiliesMolecule inhibitorsLysine modificationDemethylasesMethylationTreatment of cancerEnzymeImmune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes
Vesely M, Kidacki M, Gaule P, Gupta S, Chan N, Han X, Yeung J, Chen L. Immune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes. Journal Of Investigative Dermatology 2023, 144: 106-115.e4. PMID: 37562584, DOI: 10.1016/j.jid.2023.07.008.Peer-Reviewed Original ResearchConceptsCD11b myeloid cellsImmune inhibitory moleculesPD-L1 expressionVISTA expressionMyeloid cellsFuture potential therapeutic targetsPD-L1/B7Tumor microenvironmentInhibitory moleculesMultiplexed quantitative immunofluorescencePrimary cutaneous melanomaImmunosuppressive tumor microenvironmentNegative prognostic biomarkerCurrent clinical trialsPotential therapeutic targetCause mortalityCritical cell typesPD-L1Poor outcomeTreatment of cancerMelanoma recurrenceCutaneous melanomaClinical trialsPrognostic biomarkerT cellsOocyte Cryopreservation for Medical and Planned Indications: A Practical Guide and Overview
Han E, Seifer D. Oocyte Cryopreservation for Medical and Planned Indications: A Practical Guide and Overview. Journal Of Clinical Medicine 2023, 12: 3542. PMID: 37240648, PMCID: PMC10218997, DOI: 10.3390/jcm12103542.Peer-Reviewed Original ResearchOocyte cryopreservationAge-related fertility declineOvarian follicular lossFirst successful pregnancyElective oocyte cryopreservationFollicular lossGonadotoxic therapySuccessful pregnancyTreatment of cancerBiologic childrenFollicular fluidOvarian folliclesNarrative reviewMature oocytesOocytesPregnancyPatientsTherapyCancerFolliclesDelayed cancer diagnosis in the pregnant patient: navigating a complex medical and ethical dilemma
Revzin M, Solomon N, Langdon J, Czeyda-Pommersheim F, Menias C. Delayed cancer diagnosis in the pregnant patient: navigating a complex medical and ethical dilemma. Abdominal Radiology 2023, 48: 1599-1604. PMID: 36951988, DOI: 10.1007/s00261-023-03860-x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsEpidemiology and psychiatric correlates of cancer among homeless and unstably housed veterans in the VA healthcare system
Tsai J, Szymkowiak D, Zullig L. Epidemiology and psychiatric correlates of cancer among homeless and unstably housed veterans in the VA healthcare system. Cancer Epidemiology Biomarkers & Prevention 2023, 32: 617-624. PMID: 36791363, DOI: 10.1158/1055-9965.epi-22-1154.Peer-Reviewed Original ResearchConceptsSuicidal ideation/behaviorSubstance use disordersUse disordersVA health care systemVeterans Affairs administrative dataCommon primary siteCancer diagnosisIntrahepatic bile ductsRisk of cancerVA healthcare systemAlcohol use disorderCorrelates of cancerTypes of cancerHealth care systemIncident cancerTreatment of cancerBile ductIncidence rateHigh prevalenceLower riskPsychiatric correlatesPsychiatric characteristicsPsychiatric disordersPrimary sitePsychiatric conditionsPhosphoproteomic analysis of metformin signaling in colorectal cancer cells elucidates mechanism of action and potential therapeutic opportunities
Salovska B, Gao E, Müller‐Dott S, Li W, Cordon C, Wang S, Dugourd A, Rosenberger G, Saez‐Rodriguez J, Liu Y. Phosphoproteomic analysis of metformin signaling in colorectal cancer cells elucidates mechanism of action and potential therapeutic opportunities. Clinical And Translational Medicine 2023, 13: e1179. PMID: 36781298, PMCID: PMC9925373, DOI: 10.1002/ctm2.1179.Peer-Reviewed Original ResearchConceptsColorectal cancerLong-term metformin treatmentType 2 diabetesCRC cell linesColorectal cancer cellsBiguanide drug metforminPotential therapeutic opportunitiesMechanism of actionPharmacodynamic interactionsMetformin treatmentTreatment of cancerCRC cellsCell proliferation assaysClinical trialsBcl-2/Bcl-xL inhibitorMetforminDrug metforminTherapeutic opportunitiesProliferation assaysCancer cellsPotential cancer therapeuticsPotential roleExpression levelsCell linesCancer therapeutics
2022
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC
Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai W, Girardi M, Gru A, Guenova E, Hodak E, Hoppe R, Kempf W, Kim E, Lechowicz MJ, Ortiz-Romero P, Papadavid E, Quaglino P, Pittelkow M, Prince HM, Sanches JA, Sugaya M, Vermeer M, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick J. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood 2022, 140: 419-437. PMID: 34758074, PMCID: PMC9353153, DOI: 10.1182/blood.2021012057.Peer-Reviewed Original ResearchConceptsPrimary cutaneous lymphomasNon-Hodgkin lymphomaCutaneous lymphomasMycosis fungoides/Sézary syndromeCutaneous Lymphoma Task ForceInvestigator-initiated trialPotential prognostic factorsNumber of patientsClinical trial guidelinesClinical trial designExtracutaneous diseaseSézary syndromePrognostic factorsTreatment of cancerTrials guidelinesClinical trialsComparative efficacyTrial designNumber of subtypesEuropean OrganizationNew treatmentsLymphomaResponse criteriaTherapeutic agentsStudy designAlloantigen-specific Chimeric Antigen Receptor Regulatory T cell therapy in non-human primate islet transplantation
Ellis G, Coker K, Winn D, Deng M, Shukla D, Bhoj V, Milone M, Wang W, Liu C, Naji A, Duran-Struuck R, Riley J. Alloantigen-specific Chimeric Antigen Receptor Regulatory T cell therapy in non-human primate islet transplantation. The Journal Of Immunology 2022, 208: 175.21-175.21. DOI: 10.4049/jimmunol.208.supp.175.21.Peer-Reviewed Original ResearchCAR-TregsLarge animal modelPeripheral bloodIslet transplantationT cellsAnimal modelsRegulatory T cell therapyArtificial antigen presenting cellsCAR-Treg therapyEffector T cellsT-cell therapyAntigen presenting cellsOptimization of therapyType 1 diabetesCAR T cellsExpanded TregsTreg therapyAdoptive transferGraft rejectionAdoptive therapyDiabetic recipientsImmunosuppressive agentsNegative recipientsTreatment of cancerBlood glucoseAHCC®, a Standardized Extract of Cultured Lentinula Edodes Mycelia, Promotes the Anti-Tumor Effect of Dual Immune Checkpoint Blockade Effect in Murine Colon Cancer
Park HJ, Boo S, Park I, Shin MS, Takahashi T, Takanari J, Homma K, Kang I. AHCC®, a Standardized Extract of Cultured Lentinula Edodes Mycelia, Promotes the Anti-Tumor Effect of Dual Immune Checkpoint Blockade Effect in Murine Colon Cancer. Frontiers In Immunology 2022, 13: 875872. PMID: 35514996, PMCID: PMC9066372, DOI: 10.3389/fimmu.2022.875872.Peer-Reviewed Original ResearchConceptsDual immune checkpoint blockadeImmune checkpoint blockadeAnti-tumor effectsCheckpoint blockadeBearing miceStandardized extractTumor growthMC38 tumor-bearing miceGut microbiomePD-1/CTLATumor-infiltrating CD8Cell functionCancer bearing miceT cell functionKi-67 expressionImmune cell functionMurine colon cancerTumor bearing miceTumor-bearing miceTreatment of cancerTreatment strategiesT cellsTherapeutic effectGranzyme BColon cancer
2021
766 Toward safe, systemic delivery of synthetic TLR7/8 agonists using Bottlebrush Prodrugs (BPDs)
Bhagchandani S, Milling L, Liu B, Fessenden T, Spranger S, Johnson J, Irvine D. 766 Toward safe, systemic delivery of synthetic TLR7/8 agonists using Bottlebrush Prodrugs (BPDs). Journal For ImmunoTherapy Of Cancer 2021, 9: a801-a801. DOI: 10.1136/jitc-2021-sitc2021.766.Peer-Reviewed Original ResearchTLR reporter cellsSystemic deliveryAnti-PD-1 antibody treatmentMC38 colon cancer modelImidazoquinoline derivativesToll-like receptor agonistsSerum cytokine levelsMaximum tolerable doseSystemic side effectsImproved survival ratesReporter cellsAnti-tumor efficacyColon cancer modelCytokine levelsMetastatic diseaseTLR agonistsTLR7/8 agonistAntibody treatmentTLR activationTreatment of cancerTolerable doseReceptor agonistIntravenous administrationTopical solutionSide effectsCancer Care in Low- and Middle-Income Countries Affected by Humanitarian Crises
Alawa J, Coutts A, Khoshnood K. Cancer Care in Low- and Middle-Income Countries Affected by Humanitarian Crises. 2021, 539-574. DOI: 10.1007/978-3-030-36811-1_215.Peer-Reviewed Original ResearchMiddle-income countriesBurden of cancerCancer careCancer preventionCancer incidenceNoncommunicable diseasesFacility-based interventionsChronic noncommunicable diseasesComprehensive cancer preventionSpecialized health servicesCommunity-based interventionsHigher cancer incidenceSurgical treatmentSpecialist careCancer RegistryTreatment of cancerDescriptive epidemiologyClinical guidelinesOutpatient interventionMortality ratePeer-reviewed publicationsTreatment servicesHealth servicesCancerOlder populationAdverse events induced by immune checkpoint inhibitors
Perdigoto AL, Kluger H, Herold KC. Adverse events induced by immune checkpoint inhibitors. Current Opinion In Immunology 2021, 69: 29-38. PMID: 33640598, PMCID: PMC8122053, DOI: 10.1016/j.coi.2021.02.002.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAutoantibodiesAutoantigensAutoimmune DiseasesAutoimmunityCytotoxicity, ImmunologicDrug-Related Side Effects and Adverse ReactionsGene-Environment InteractionGenetic Predisposition to DiseaseHumansImmune Checkpoint InhibitorsImmunotherapyLymphocyte ActivationNeoplasmsT-LymphocytesConceptsImmune checkpoint inhibitorsCheckpoint inhibitorsAdverse eventsT cellsImmune related adverse eventsEmergence of autoantibodiesRelated adverse eventsAnti-tumor responseAutoreactive T cellsActivated T cellsAutoimmune mechanismsTreatment of cancerAutoimmune diseasesInflammatory responsePredictive valueHost factorsToxic effectsInhibitorsDirect effectOngoing investigationAutoantibodiesCellsAutoimmunityPathogenesisCancerCancer Care in Low- and Middle-Income Countries Affected by Humanitarian Crises
Alawa J, Coutts A, Khoshnood K. Cancer Care in Low- and Middle-Income Countries Affected by Humanitarian Crises. 2021, 1-36. DOI: 10.1007/978-3-319-74365-3_215-1.Peer-Reviewed Original ResearchMiddle-income countriesBurden of cancerCancer careCancer preventionCancer incidenceNoncommunicable diseasesFacility-based interventionsChronic noncommunicable diseasesComprehensive cancer preventionSpecialized health servicesCommunity-based interventionsHigher cancer incidenceSurgical treatmentSpecialist careCancer RegistryTreatment of cancerDescriptive epidemiologyClinical guidelinesOutpatient interventionMortality ratePeer-reviewed publicationsTreatment servicesHealth servicesCancerOlder populationAn azo dye for photodynamic therapy that is activated selectively by two-photon excitation
Juvekar V, Lim C, Lee D, Park S, Song G, Kang H, Kim H. An azo dye for photodynamic therapy that is activated selectively by two-photon excitation. Chemical Science 2021, 12: 427-434. PMID: 34163605, PMCID: PMC8178981, DOI: 10.1039/d0sc05686c.Peer-Reviewed Original ResearchTwo-photon excitationReactive oxygen species (ROS)-generation abilityNegligible dark toxicityType I processAzo groupOrganic dyesMild conditionsTwo-photon photodynamic therapyEfficient PDT applicationsAzo dyesROS generation abilitySmall moleculesTP-PDTAzoPDT propertiesDyePDT applicationsDark toxicityTwo-photonPhotosensitizerPhotodynamic therapyI processGeneration abilityExcitationTreatment of cancer
2020
Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic.
Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Geyer MB, Gojo I, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Lyman GH, Mukherjee S, Perez LE, Rosovsky RP, Roy V, Rugo HS, Vasu S, Wadleigh M, Westervelt P, Becker PS. Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic. Journal Of The National Comprehensive Cancer Network 2020, 19: 1-4. PMID: 32871558, PMCID: PMC9730290, DOI: 10.6004/jnccn.2020.7610.Peer-Reviewed Original ResearchErythrocyte-stimulating agentsHematopoietic growth factorsGrowth factorSARS-CoV-2 infectionPandemic SARS-CoV-2 infectionGranulocyte colony-stimulating factorColony-stimulating factorTreatment of cancerThrombopoietin mimeticsHigh riskSuch growth factorsStimulating agentsPatientsCancerCOVID-19 eraCOVID-19 pandemicInfectionHigh-risk environmentsNeutropeniaThrombocytopeniaMorbidityChemotherapyFactorsAnemiaGroupThe Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
Taube JM, Akturk G, Angelo M, Engle EL, Gnjatic S, Greenbaum S, Greenwald NF, Hedvat CV, Hollmann TJ, Juco J, Parra ER, Rebelatto MC, Rimm DL, Rodriguez-Canales J, Schalper KA, Stack EC, Ferreira CS, Korski K, Lako A, Rodig SJ, Schenck E, Steele KE, Surace MJ, Tetzlaff MT, von Loga K, Wistuba II, Bifulco CB, . The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation. Journal For ImmunoTherapy Of Cancer 2020, 8: e000155. PMID: 32414858, PMCID: PMC7239569, DOI: 10.1136/jitc-2019-000155.Peer-Reviewed Original ResearchConceptsMultiplex immunohistochemistryImmune cell subsetsImmunotherapy of cancerRoutine clinical practiceMultiplex immunofluorescence analysisDigital spatial profilingMIF assayTask ForceTreatment of cancerCell subsetsPractice guidelinesBest practice guidelinesAcademic centersClinical practiceImmune systemTumor microenvironmentImmunohistochemistryTumor cellsBiomarker studiesCancer statementsChromogenic immunohistochemistryImmunotherapyImmunofluorescence analysisConsecutive stainingCancerHow Artificial Intelligence Will Impact Colonoscopy and Colorectal Screening
Shung DL, Byrne MF. How Artificial Intelligence Will Impact Colonoscopy and Colorectal Screening. Gastrointestinal Endoscopy Clinics Of North America 2020, 30: 585-595. PMID: 32439090, DOI: 10.1016/j.giec.2020.02.010.Peer-Reviewed Original ResearchConceptsArtificial intelligenceArtificial intelligence-based technologiesDeep learning algorithmsComputer-assisted diagnosisComputer-assisted detectionLearning algorithmCenter efficiencyIntelligenceUnnecessary costsKey challengesColorectal screeningWorkflowDetection rateLow-risk polypsAdenoma detection rateTechnologyQuality of screeningTreatment of cancerInterpretabilityGastrointestinal tractAlgorithmClinical integrationCostPolypsDiagnosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply